Roivant Sciences Ltd. (ROIV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
11-12 St. James's Square
London, SW1Y 4LB
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 2074 003 347
Website
Sector
Healthcare
Industry
Biotechnology
Employees
908
First IPO Date
December 08, 2020
| Name | Title | Pay | Year Born |
| Matthew Gline | Chief Executive Officer & Director | 5.72M | 1984 |
| Eric Venker | President & Chief Executive Officer of Immunovant | 6.67M | 1987 |
| Jennifer Humes | Chief Accounting Officer | 324,640 | 1982 |
| Richard Pulik | Chief Financial Officer | 1.55M | 1980 |
| Mayukh Sukhatme | President, Chief Investment Officer & Director | 81.64M | 1976 |
| Frank Torti | President & Vant Chair | 0 | 1979 |
| Huafeng Xu | Chief Technology Officer | 0 | N/A |
| Alex Gasner | Executive Vice President of Roivant Health | 0 | N/A |
| Ian Rosenblum | Chief Information Officer | 0 | N/A |
| Josh Chen | General Counsel | 0 | N/A |
| Kelly Graff | Head of People | 0 | N/A |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.